Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial

Giugliano, Robert; Keech, Anthony; Murphy, Sabina; Huber, Kurt; TOKGÖZOĞLU, SADBERK; Lewis, Basil; Ferreira, Jorge; Pineda, Armando; Somaratne, Ransi; Sever, Peter; Pedersen, Terje; Sabatine, Marc

doi:10.1001/jamacardio.2017.3944

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial

Atıf İçin Kopyala

Giugliano R. P. , Keech A., Murphy S. A. , Huber K., TOKGÖZOĞLU S. L. , Lewis B. S. , ...Daha Fazla

JAMA CARDIOLOGY, cilt.2, ss.1385-1391, 2017 (SCI İndekslerine Giren Dergi)

Cilt numarası: 2 Konu: 12
Basım Tarihi: 2017
Doi Numarası: 10.1001/jamacardio.2017.3944
Dergi Adı: JAMA CARDIOLOGY
Sayfa Sayıları: ss.1385-1391

Özet

IMPORTANCE Current guidelines for atherosclerotic cardiovascular disease focus on high-intensity statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL-C) level of less than 70 mg/dL for the highest-risk patients. Whether further reduction of LDL-C beyond these boundaries would be beneficial is unknown.